Extramedullary relapse of AML after allogeneic hematopoietic SCT (HSCT) is rare and less well-defined than systemic disease relapse. In a European Group for Blood and Marrow Transplantation (EBMT) study, the incidence of extramedullary relapse after HSCT was as low as 0.65% in AML. 1 However, other studies have reported an incidence of up to 20% among long-term survivors. [1] [2] [3] [4] [5] [6] There are no established guidelines for clinical decision making pertaining to the treatment of extramedullary relapse after HSCT. 7 Common practice entails a combination of localized radiation, systemic chemotherapy, immunotherapy with donor lymphocyte infusions (DLI), and repeated transplantation if possible. We present in this report our experience in treating two patients with extramedullary non-hematological disease in the setting of relapsed AML previously treated with HSCT, DLI, chemotherapy and radiotherapy.
Patient no. 1 A 34-year-old man presented with diffuse maculopapular rash with multiple erythematous skin nodules. BM studies were negative. Skin biopsy was consistent with monoblastic leukemia cutis. He received induction with idarubicin/cytarabine in December 2010 with disappearance of all skin lesions and negative skin biopsy. He then received the first consolidation (idarubicin/ cytarabine) followed by allogeneic HSCT in February 2011 with a preparative regimen of fludarabine, busulfan and thymoglobulin. He achieved full donor chimerism at Days 30 and 100, with no evidence of GVHD. Five months after transplantation, he developed three small skin nodules, the biopsy of which confirmed early relapse. He received salvage chemotherapy with cladribine, high-dose cytarabine and G-CSF (CLAG regimen) in August 2011 followed by DLI (1.0 Â 10 7 cells/kg) as well as local radiotherapy. Unfortunately, new skin lesions rapidly reappeared at other sites. In addition, the patient developed a right s.c. groin mass of 3 Â 2 cm 2 that was positive for myeloid leukemia with no other evidence of systemic disease by computed tomography (CT) scan and BM evaluation. The patient was started on a reduced dose of azacitidine (32 mg/m 2 for 5 days) in February 2012 with good tolerance and no hematological toxicity. Subsequently, he received a full dose azacitidine (75 mg/m 2 for 7 days) monthly for five cycles. The patient had an excellent response to azacitidine ( Figure 1) ; some skin nodules started to regress after the first cycle while others stabilized with no new lesions. Furthermore, the response was more noticeable after the third cycle. The right groin mass decreased significantly from 4.2 Â 3.3 cm 2 to 2.1 Â 2 cm 2 . Repeated BM evaluation was always negative. Unfortunately, new skin lesions appeared after the fifth cycle and were treated with localized radiotherapy. He recently developed systemic relapse with muscle, lung and liver involvement and passed away from multi-organ failure despite aggressive chemotherapy. . After the first cycle, she had a rapid but transient resolution of her gingival hypertrophy. BM examination after the second cycle was negative for leukemia, karyotype was of donor origin (46, XY), and chimerism was 100% donor. Gingival hypertrophy did not improve, and it even increased after additional treatment with FLAG and DLI. She was started in April 2011 on azacitidine 75 mg/m 2 /day for 7 days every 28 days. She had a gradual response, and after the 4th cycle the gingival hypertrophy significantly decreased in size, with almost complete resolution after the 8th cycle (Figure 2 ). Thus, she was maintained on azacitidine with negative BM evaluation every 3 months. She has received her 17th dose of azacitidine in August 2012 and she is doing well with normal life activities and small stable gingival lesion.
Extramedullary relapse after HSCT in AML is rare with a median time to diagnosis longer than to BM relapse (about 12-17 months vs 3-6 months, respectively). 1, 3, 6 Although the prognosis is poor for extramedullary relapse, it is better than for systemic relapse, with a 2-year OS of 11-38%. 1, 3 Therefore, the goal of therapy should be to prevent systemic relapse. Figure 1 . Regression of the skin lesion after treatment with 5-azacitidine: right leg erythematous, skin nodule (leukemia cutis) before starting azacitidine (a). The lesion became more flat and less erythematous and smaller after the second cycle (b). Complete resolution of the nodule with residual dark discoloration of the skin after the fifth cycle (c).
The DNA hypomethylating agent 5-azacitidine has been studied in patients with AML/MDS post allogeneic HSCT as maintenance therapy, salvage therapy and as treatment of imminent relapse. De Lima et al. 8 showed that maintenance azacitidine at 32 mg/m 2 / day for 5 days was safe and could be administered after allogeneic transplant for at least four cycles to heavily pretreated AML/MDS patients. This treatment may prolong event-free and OS, and more cycles may be associated with greater benefit. Platzbecker et al. 9 demonstrated that minimal residual disease-triggered treatment with azacitidine appears to be an effective strategy for preventing or substantially delaying hematologic relapse with an acceptable safety profile in patients with MDS or AML after HSCT. Serrao et al. 10 have recently reported on a 62-year-old man with CMML who developed an isolated bone lesion in the humerus as the only extramedullary localization of his disease. 10 The patient was treated successfully with azacitidine and radiotherapy.
To the best of our knowledge, our two cases are the first reported cases that showed a very good response to 5-azacitidine in the setting of extramedullary AML after failure of allogeneic HSCT, DLI, radiotherapy and chemotherapy. The two patients responded to azacitidine with no BM relapse; one relapsed and passed away and the other is maintained on azacitidine with normal performance. These results suggest that 5-azacitidine is effective in inducing responses in the setting of extramedullary relapse of AML after failure of all treatment modalities including allogeneic HSCT. Our findings warrant further evaluation in the context of prospective clinical studies. 
